Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-548-3 | CAS number: 53423-65-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 April 2018 - 09 May 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 442E (In VItro Skin Sensitisation h-CLAT)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: DB-ALM Protocol n°158 (Skin Sensitisation h-CLAT)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- activation of dendritic cells
- Justification for non-LLNA method:
- Current REACH protocol requires In vitro / In chemico assessment before in vivo.
Test material
- Reference substance name:
- Sodium 2,4,5-trichlorobenzenesulphonate
- EC Number:
- 258-548-3
- EC Name:
- Sodium 2,4,5-trichlorobenzenesulphonate
- Cas Number:
- 53423-65-7
- Molecular formula:
- C6H2Cl3O3S.Na
- IUPAC Name:
- sodium 2,4,5-trichlorobenzenesulfonate
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- Name: STB-FR
Batch No.: 1710-06
Chemical name: Benzenesulfonic acid, 2,4,5-trichloro-, sodium salt
CAS No: 53423-65-7
Composition: 90.5% STB; 9.5% other
Molecular Weight: 283.494 g/mol
Purity: 90.5%
Physical State: solid powder
Colour: white
Log KOW: not specified by the sponsor
Stability: stable
Storage Conditions: at room temperature
Expiry Date: October 2019
In vitro test system
- Details on the study design:
- The in vitro human cell line activation test (h-CLAT) enables detection of the sensitising potential of a test item by addressing the third molecular key event of the adverse outcome pathway (AOP), namely dendritic cell (DC) activation, by quantifying the expression of the cell surface markers CD54 and CD86 in the human monocytic cell line THP-1. The expression of the cell surface markers compared to the respective solvent controls is used to support discrimination between skin sensitiser and non-sensitisers. Prior to the main study the cell batch was checked for its reactivity towards known positive and negative controls and was found to be acceptable for further testing. In this study, the test substance was dissolved in DMSO. For the dose finding assay stock solutions with concentrations ranging from 500.00 mg/mL to 3.91 mg/mL were prepared by a serial dilution of 1:2. Cells were incubated with the test item for 24 h at 37°C. After exposure cells were stained with propidium iodide and cell viability was measured by FACS analysis.
The test meets acceptance criteria if:
• the cell viability of the solvent controls is >90%,
• the cell viability of at least four tested doses of the test item in each run is >50%,
• the RFI values of the positive control (DNCB) is ≥150% for CD86 and ≥200% for CD54 at a cell viability of >50%,
• the RFI values of the solvent control is not ≥150% for CD86 and not ≥200% for CD54,
• the MFI ratio of CD86 and CD54 to isotype IgG1 control for the medium and DMSO control, is >105%.
Sensitising potential of the test item was predicted from the mean percentage expression of CD86 and CD54. Any test chemical tested by the h-CLAT was considered positive if the RFI of CD86 was equal to or greater than 150% at any tested dose at a cell viability ≥ 50% in at least two independent runs or if the RFI of CD54 was equal to or greater than 200% at any tested dose at a cell viability ≥ 50% in at least two independent runs or if the RFIs of both the CD86 and CD54 were equal to or are greater than 150% and 200% respectively at any tested dose at a cell viability ≥ 50% in at least two independent runs. In case of not concordant results a third run would be conducted to make the final prediction. Otherwise the results were considered as inconclusive.
A negative test result of a test item was only accepted if the cell viability at a concentration of 1.2 x CV75 is <90%. In contrast, a positive test outcome was accepted irrespective of cell viabilities >90% at a concentration of 1.2 x CV75. If no CV75 could be derived negative test results can be accepted when the test item is tested at the highest soluble concentration (5000 µg/mL for 0.9% NaCl solution; 1000 µg/mL for DMSO or a different organic solvent) even if the cell viability is >90%.
Results and discussion
- Positive control results:
- The acceptance criteria for the positive control were fulfilled.
In vitro / in chemico
Resultsopen allclose all
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: CD86 Relative Flourescence Intensity (RFI, %)
- Value:
- 81
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: CD86 Relative Flourescence Intensity (RFI, %)
- Value:
- 95
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: CD54 Relative Flourescence Intensity (RFI, %)
- Value:
- 103
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: CD54 Relative Flourescence Intensity (RFI, %)
- Value:
- 114
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- No cytotoxic effects were observed for the cells treated with the test item. Relative cell viability at the highest test item concentration was reduced to 92.4% (CD86), 91.8% (CD54) and 91.5% (isotype IgG1 control) in the first experiment and to 87.6% (CD86), 87.0% (CD54) and 85.4% (isotype IgG1 control) in the second experiment. The expression of the cell surface marker CD86 was not upregulated above the threshold of 150% in any of the experiments. The expression of cell surface marker CD54 was not upregulated above the threshold of 200% in any of the experiments. Therefore, the test item is not considered to be a skin sensitiser. The controls confirmed the validity of the study for all experiments.
Any other information on results incl. tables
CD54 and CD86 Expression Experiment 1
Sample |
Conc. |
Cell Viability [%] |
Mean Fluorescence Intensity |
corrected Mean Fluorescence Intensity |
Relative Flourescence Intensity (RFI) |
Ratio Isotype IgG1 to [%] |
|||||||
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
CD86 |
CD54 |
CD86 |
CD54 |
||
Medium Control |
- |
94.8 |
94.2 |
94.2 |
4504 |
1496 |
854 |
3650 |
642 |
89 |
86 |
527 |
175 |
Solvent Control |
0.20% |
93.4 |
93.6 |
93.6 |
4829 |
1457 |
712 |
4117 |
745 |
100 |
100 |
678 |
205 |
DNCB |
4.00 |
82.0 |
82.8 |
82.3 |
11458 |
2405 |
702 |
10756 |
1703 |
261 |
229 |
1632 |
343 |
STB-FR |
1000 |
92.4 |
91.8 |
91.5 |
4088 |
1599 |
1022 |
3066 |
577 |
74 |
77 |
400 |
156 |
833.33 |
92.3 |
92.5 |
92.4 |
3846 |
1601 |
945 |
2901 |
656 |
70 |
88 |
407 |
169 |
|
694.44 |
89.0 |
88.7 |
89.3 |
4176 |
1692 |
924 |
3252 |
768 |
79 |
103 |
452 |
183 |
|
578.70 |
90.8 |
91.3 |
91.9 |
4196 |
1700 |
958 |
3238 |
742 |
79 |
100 |
438 |
177 |
|
482.25 |
91.1 |
91.5 |
90.4 |
4073 |
1569 |
924 |
3149 |
645 |
76 |
87 |
441 |
170 |
|
401.88 |
91.9 |
91.9 |
92.0 |
4052 |
1567 |
904 |
3148 |
663 |
76 |
89 |
448 |
173 |
|
334.90 |
92.6 |
93.5 |
93.3 |
3854 |
1535 |
923 |
2931 |
612 |
71 |
82 |
418 |
166 |
|
279.08 |
92.6 |
93.4 |
92.7 |
4255 |
1596 |
924 |
3331 |
672 |
81 |
90 |
460 |
173 |
CD54 and CD86 Expression Experiment 2
Sample |
Conc. |
Cell Viability [%] |
Mean Fluorescence Intensity |
corrected Mean Fluorescence Intensity |
Relative Flourescence Intensity (RFI) |
Ratio Isotype IgG1 to [%] |
|||||||
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
CD86 |
CD54 |
CD86 |
CD54 |
||
Medium Control |
- |
95.6 |
94.8 |
94.8 |
3501 |
1395 |
752 |
2749 |
643 |
90 |
110 |
466 |
186 |
Solvent Control |
0.20% |
94.0 |
94.4 |
95.0 |
3793 |
1314 |
731 |
3062 |
583 |
100 |
100 |
519 |
180 |
DNCB |
4.0 |
83.1 |
83.1 |
82.1 |
9665 |
2532 |
1064 |
8601 |
1468 |
281 |
252 |
908 |
238 |
STB-FR |
1000.00 |
87.6 |
87.0 |
85.4 |
3545 |
1433 |
924 |
2621 |
509 |
86 |
87 |
384 |
155 |
833.33 |
90.2 |
88.8 |
89.0 |
3429 |
1570 |
993 |
2436 |
577 |
80 |
99 |
345 |
158 |
|
694.44 |
91.1 |
91.0 |
91.1 |
3726 |
1476 |
892 |
2834 |
584 |
93 |
100 |
418 |
165 |
|
578.70 |
91.2 |
92.5 |
92.6 |
3756 |
1432 |
853 |
2903 |
579 |
95 |
99 |
440 |
168 |
|
482.25 |
94.3 |
92.4 |
93.3 |
3695 |
1574 |
907 |
2788 |
667 |
91 |
114 |
407 |
174 |
|
401.88 |
93.7 |
93.5 |
93.4 |
3707 |
1441 |
849 |
2858 |
592 |
93 |
102 |
437 |
170 |
|
334.90 |
93.4 |
93.7 |
93.3 |
3723 |
1405 |
835 |
2888 |
570 |
94 |
98 |
446 |
168 |
|
279.08 |
94.0 |
94.5 |
93.5 |
3430 |
1344 |
839 |
2591 |
505 |
85 |
87 |
409 |
160 |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The test substance was non-sensitising in the in vitro human cell line activation test (h-CLAT) assay.
- Executive summary:
In this GLP guideline study conducted according to OECD 442E "In vitro Skin Sensitisation assays addressing the Key Event on activation of dendritic cells on the Adverse Outcome Pathway for Skin Sensitisation" human cell line activation test (h-CLAT) to assess a key event associated with skin sensitisation, namely dendritic cell activation, the test substance did not upregulate the expression of the cell surface marker in at least two independent experimental runs and thus can be regarded as not a skin sensitiser in the h-CLAT assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)